Subscribe to newsletters
Wednesday, March 13, 2013
Quadratech is sponsoring a Microparticles Meeting at the University of Leicester Tuesday 21st May 2013 A series of presentations by leading microparticles researchers from the UK and Amsterdam Medical Centre
details
Tuesday, March 12, 2013
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Raps M et al, 2013, Throm Haemost 109(4):[ahead of print] "The effect of oral contraceptives on TFPI and PS is a possible explanation for the increased risk of venous thrombosis associated with oral contraceptives"
details
Tuesday, March 12, 2013
Molecular Circuits in Thrombosis and Inflammation. Esmon CT, 2013, Throm Haemost 109 (3):416-420 "In addition to the direct prothrombotic activity of histone-DNA complexes, the complexes trigger activation of the toll-like receptors 2, 4 and 9 thereby increasing inflammatory cytokine formation and fostering thrombotic responses through the mechanisms mentioned previously."
details
Wednesday, February 06, 2013
Early Vascular Alterations in SLE and RA Patients—A Step towards Understanding the Associated Cardiovascular Risk. Jose M et al, PLOS ONE www.plosone.org 1 September 2012 Volume 7 Issue 9
details
Wednesday, February 06, 2013
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.
details
Tuesday, January 08, 2013
A study of patients in three different monitoring settings showed domiciliary-based patients had the poorest anticoagulation control.
details
Wednesday, January 02, 2013
What is already known about this subject: Observation from clinical studies have demonstrated that: • CYP2C19 genotype does not have a clinically relevant effect on active metabolite concentrations or platelet inhibition in prasugrel-treated subjects • Variability of response to clopidogrel active metabolite and reduced platelet inhibition lead to increased adverse cardiovascular events in patients with acute coronary syndromes
details
Wednesday, January 02, 2013
What is already known about this subject: A number of pharmacokinetics studies have focused on S-warfarin. These have shown that demographic factors, such as bodyweight, genetic factors, such as CYP2C9 genotype, and interacting medicines, particularly amiodarone, contribute to the interindividual estimates of clearance. What this study adds: This study not only reinforces what has previously been learned about S-warfarin, but also provides an insight into the pharmacokinetics of R-warfarin.
details
Wednesday, December 19, 2012
January 2013 Newsletter is available to download. Special points of interest: 1. Awareness of lupus anticoagulants in drug therapy 2. New product, Entamoeba histolytica IgG 3. Research portfolio grows
details
Tuesday, December 18, 2012
Quadratech supplies high quality Epigenetic Peptides and Antibodies, Custom Peptides, Custom Antibodies, Antibodies to Selected Targets and Bioactive Peptides. These have been successfully used in many research laboratories.
details
1 2 3 Next
Powered by nopcommerce